Risk of Acute Infections in New Users of Antihypertensive Drugs: An Observational Cohort Study
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.040242 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Noah Aebi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences University of Basel Basel Swit…. Hauptthemen laut MEDLINE: COVID-19, Antihypertensive Agents, Amlodipine, Hypertension. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Functional inhibitors of acid sphingomyelinase enhance human immune function in vitro. We compared the risk of acute infection in users of amlodipine, a functional inhibitor of acid sphingomyelinase, to users of other first‐line antihypertensive drugs.
Methods
We conducted a cohort study using the UK Clinical Practice Research Datalink GOLD (2000–2021). We included new monousers of amlodipine, ramipril, or bendroflumethiazide without preexisting cardiovascular disease. In 2 pairwise comparisons (amlodipine versus ramipril/bendroflumethiazide), we followed patients for as long as they were exposed to compare risk of the primary outcome (acute outpatient infections including respiratory, genitourinary, gastrointestinal infections, and sepsis) and diagnosed SARS‐CoV‐2 infections in 2020/2021 (amlodipine versus ramipril). We estimated incidence rates (IR) and IR ratios using negative binomial regression, overall and in subgroup analyses. We controlled for confounding using fine stratification on the propensity score.
Results
After propensity score weighting, we included 121 847 amlodipine versus 122 096 ramipril users and 46 368 amlodipine versus 153 660 bendroflumethiazide users. IRs for the primary outcome ranged from 38.9 per 1000 person‐years for amlodipine to 51.6/1000 person‐years for bendroflumethiazide. The weighted IR ratios for acute infections were 0.77 (95% CI, 0.75–0.80) for amlodipine versus ramipril, and 0.78 (95% CI, 0.75–0.81) for amlodipine versus bendroflumethiazide. These results were robust after excluding patients with diabetes, after restriction to patients with diagnosed hypertension, and within other subgroup analyses. Amlodipine (versus ramipril) was associated with an IR ratio for SARS‐CoV‐2 infection of 0.57 (95% CI, 0.48–0.67).
Conclusions
Amlodipine may be associated with a lower risk of acute infections compared with ramipril and bendroflumethiazide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences University of Basel Basel Switzerland.
- Hospital Pharmacy University Hospital Basel Basel Switzerland.
- University Psychiatric Clinics Basel, University Hospital Basel Basel Switzerland.
- Boston Collaborative Drug Surveillance Program Lexington MA USA.
- Boston University School of Public Health Boston MA USA.
ORCID-Profile: Noah Aebi, Christoph R Meier, Undine Lang, Julia Spoendlin
Zitieren
APA
Aebi, N., Meier, C. R., Jick, S. S., Lang, U., & Spoendlin, J. (2025). Risk of Acute Infections in New Users of Antihypertensive Drugs: An Observational Cohort Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.040242
Vancouver
Aebi N, Meier CR, Jick SS, Lang U, Spoendlin J. Risk of Acute Infections in New Users of Antihypertensive Drugs: An Observational Cohort Study. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.040242
BibTeX
@article{Aebi2025,
author = {Aebi, Noah and Meier, Christoph R and Jick, Susan S and Lang, Undine and Spoendlin, Julia},
title = {Risk of Acute Infections in New Users of Antihypertensive Drugs: An Observational Cohort Study},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.040242}
}
EUVIMED